Ionic Pharmaceuticals
Private Company
Total funding raised: $15M
Overview
Ionic Pharmaceuticals is a private, preclinical-stage biotech developing a novel nanoparticle drug delivery platform with a claimed 50x improvement in tumor accumulation efficiency. The company, a Boston University spin-out, is applying its materials science expertise across two initial sectors: oncology drug delivery and wound care. Led by a team with prior drug development and commercialization success, including a co-inventor of the blockbuster drug Abraxane, Ionic is currently funded by NIH grants and awards as it works towards commercialization.
Technology Platform
Patented nanoparticle platform using a Materials-Based Targeting (MBT) strategy, leveraging intrinsic physicochemical properties of engineered polymers (e.g., surface charge, responsiveness to pathological cues) to achieve highly efficient targeted drug delivery, with claimed 50x improvement in tumor accumulation.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
In drug delivery, Ionic faces competition from numerous biotechs and pharma companies developing next-gen nanoparticles, antibody-drug conjugates (ADCs), and other targeting modalities. In wound care, it must differentiate from established players with a wide range of advanced dressings. Its key differentiator is the Materials-Based Targeting approach, which must prove clinically superior to biological ligand-based systems.